Lupin receives approval from US FDA for Turqoz®

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP) 0.3 mg/0.03 mg, to market a generic equivalent of Lo/Ovral-28 (Norgestrel and Ethinyl Estradiol Tablets) 0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC. This product will be manufactured at Lupin's Pithampur facility in India.

Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 988.25 as compared to the previous close of Rs. 985.35. The total number of shares traded during the day was 34997 in over 2196 trades.

The stock hit an intraday high of Rs. 994.55 and intraday low of 977.20. The net turnover during the day was Rs. 34549985.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Approval USFDA ANDA Turqoz Norgestrel EthinylEstradiolTablets